Publication:
Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study

Simple item page
dc.contributor.authorsBaranauskaite, Asta; Raffayová, Helena; Kungurov, Nv; Kubanova, Anna; Venalis, Algirdas; Helmle, Laszlo; Srinivasan, Shankar; Nasonov, Evgeny; Vastesaeger, Nathan
dc.date.accessioned2022-03-02T05:37:22Z
dc.date.accessioned2026-01-11T19:13:50Z
dc.date.available2022-03-02T05:37:22Z
dc.date.issued2012-04
dc.identifier.doi10.1136/ard.2011.152223
dc.identifier.issn0003-4967, 1468-2060
dc.identifier.issue4
dc.identifier.pages541-548
dc.identifier.urihttps://hdl.handle.net/11424/218379
dc.identifier.volume71
dc.language.isoeng
dc.relation.urihttps://ard.bmj.com/lookup/doi/10.1136/ard.2011.152223
dc.titleInfliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
dc.title.alternativeInfliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients
dc.typearticle
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
270.46 KB
Format:
Adobe Portable Document Format
Download

Collections

Araştırma Çıktıları